In topical drug development, even the smallest variable can have a significant impact on product performance. At Coral Drugs, we recognize that up to 90% of formulation challenges in topical APIs can be traced back to a single, often underestimated factor: uncontrolled particle size. When particle size is inconsistent, it can compromise dissolution, absorption rate, uniformity, and even long-term stability, ultimately affecting both therapeutic efficacy and patient experience.

This challenge becomes even more critical for potent topical corticosteroids such as Clobetasol Propionate and Fluocinonide. These APIs demand extremely tight particle size specifications to ensure proper dispersion in creams, gels, ointments, and lotions. Variability at this stage can lead to batch failures, inconsistent bioavailability, and delayed regulatory approval.

To address this, Coral Drugs has built deep expertise in developing and delivering controlled particle size APIs tailored specifically for topical formulations. Our advanced micronization infrastructure, precise process engineering, and comprehensive analytical capabilities enable us to achieve highly consistent and reproducible particle size distributions. Every batch undergoes rigorous quality assessment using techniques like laser diffraction and high-resolution microscopy, ensuring accuracy from the micron level upward.

This precision-driven approach not only improves formulation reliability but also enhances stability, reduces development time, and strengthens downstream manufacturability for our partners. With fully integrated systems that maintain control from raw materials to final API release, Coral Drugs stands as a trusted partner for companies seeking dependable, high-performance topical APIs.

Beyond technical execution, we collaborate closely with formulation scientists and development teams to understand the exact performance parameters required. This partnership approach helps eliminate guesswork, supports faster scale-up, and results in APIs that integrate smoothly into final dosage forms with minimal reformulation.

As regulatory expectations grow stricter and markets demand higher consistency, the need for particle size–controlled APIs continues to rise. Coral Drugs remains committed to advancing this capability through ongoing R&D, cutting-edge equipment, and a relentless focus on quality, ensuring our customers always receive APIs built for reliability and performance.

Follow us on LinkedIn for scientific insights, announcements, and industry updates.

‍